Characterisation of the P53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines

International Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 913-918

  Pestell, Katharine E ^a   Medlow, Clare J ^a   Titley, Jenny C ^a   Kelland, Lloyd R ^a   Walton, Michael I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIS AMMINEDICHLORO(2 METHYLPYRIDINE) PLATINUM(II); CISPLATIN; MESSENGER RNA; PLATINUM DERIVATIVE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; OVARY CANCER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CARCINOMA; CISPLATIN; DNA PRIMERS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031873441     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980911)77:6<913::AID-IJC19>3.0.CO;2-1     Document Type: Article

References (21)

1. CIP1/WAF1 proteins following γ-irradiation of human lymphoma cells. Cancer Res., 55, 2387-2393 (1995).
2. BRACHMAN, D.G., BECKETT, M., GRAVES, D., HARAF, D., VOKES, E. and WEICHSELBAUM, R.R., p53 Mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53, 3667-3669 (1993).
3. BROWN, R., CLUGSTON, C., BURNS, P., EDLIN, A., VASEY, P., VOJTÊSEC, B. and KAYE, S.B., Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55, 678-684 (1993).
4. CHU, G., Cellular responses to cisplatin. J. biol. Chem., 269, 787-790 (1994)
5. DE FEUDIS, P., DEBERNARDIS, D., BECCAGLIA, P., VALENTI, M., GRANIELA SIR É, E., ARZANI, D., STANZIONE, S., PARODI, S., D'INCALCI, M., RUSSO, P. and BROGGINI, M., DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Brit. J. Cancer, 76, 474-479 (1997).
6. ELIOPOULOS, A.G., KERR, D.J., HEROD, J., HODGKINS, L., KRAJEWSKI, S., REED, J.C. and YOUNG, L.S., The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11, 1217-1228 (1995).
7. FRITSCHE, M., HAESSLER, C. and BRANDNER, G., Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA-damaging agents. Oncogene, 8, 307-318 (1993).
8. GALLARDO, D., DRAZAN, K.E. and MCBRIDE, W.H., Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res., 56, 4891-4893 (1996).
9. HEROD, J.J., ELIOPOULOS, A.G., WARWICK, J., NIEDOBITEK, G., YOUNG, L.S. and KERR, D.J., The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res., 56, 2178-2184 (1996).
10. HOLFORD, J., SHARP, S.Y., MURRER, B.A., ABRAMS, M. and KELLAND, L.R., In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer, 77, 366-373 (1997).
11. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. and HARRIS, C.C., p53 mutations in human cancers. Science, 253, 49-53 (1991).
12. HUANG, W.C., CHAI, C.Y., HUANG, J.S. and CHUANG, L.Y., Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum. Pathol., 27, 1324-1328 (1996).
13. KO, L.J. and PRIVES, C., p53: puzzle and paradigm. Genes Develop., 10, 1054-1072 (1996).
14. MCILWRATH, A.J., VASEY, P.A., Ross, G.M. and BROWN, R., Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54, 3718-3722 (1994).
15. O'CONNOR, P.M., and 12 OTHERS, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57, 4285-1300 (1997).
16. PEROG, P., GIAROLA, M., RIGHETTI, S.C., SUPINO, R., CASERINI, C., DELIA, D., PIEROTTI, M.A., MIYASHITA, T., REED, J.C. and ZUNINO, F., Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56, 556-562 (1996).
17. SHELLING, A.N., Role of p53 in drug resistance in ovarian cancer. Lancet, 349, 744-745 (1997).
18. TEYSSIER, J.R., BÉNARD, J., FERRE, D., DA SILVA, J. and RENAUD, L., Drug-related chromosomal changes in chemoresistant human ovarian carcinoma cells. Cancer Genet. Cytogenet., 39, 35-43 (1989).
19. WRIGHT, P.A., TIDD, D.M. and GREEN, J.A., Characterisation of the spectrum of p53 mutations in human ovarian cancer cell lines and ovarian tumours [abstract]. BACR, ACP and RSM (Oncology section) joint winter meeting symposium (1994).
20. WU, G.S. and EL-DEIRY, W.S., Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin. Cancer Res., 2, 623-633 (1996).
21. YAGINUMA, Y. and WESTPHAL. H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res., 52, 4196-1199 (1992).